Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Polatuzumab Vedotin + Rituximab + Bendamustine in Japanese R/R DLBCL
jRCT2080223990Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Complete response rate (CRR). Started Aug 2018; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2080223990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223990.